Characterization of Candida parapsilosis complex isolates

Clinical Microbiology and Infection

Volumn 17, Issue 3, 2011, Pages 418-424

  de Toro Crespo, M ^a   Torres, M J ^a   Maite, Ruiz ^a   Aznar, J ^b  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Amphotericin B; Anidulafungin; Biofilms; Candida parapsilosis; Voriconazole

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; VORICONAZOLE;

ARTICLE; BIOFILM; BLOOD; BLOOD SAMPLING; CANDIDA; CANDIDA METAPSILOSIS; CANDIDA ORTHOPSILOSIS; CANDIDA PARAPSILOSIS; CONTROLLED STUDY; FUNGUS ISOLATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PLANKTON; PRIORITY JOURNAL; SPAIN; TERTIARY HEALTH CARE;

CANDIDA METAPSILOSIS; CANDIDA ORTHOPSILOSIS; CANDIDA PARAPSILOSIS;

EID: 79751502140     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2010.03302.x     Document Type: Article

References (30)

1. Almirante BJ, Alonso-Tarres L, Rodriguez-Tudela JL, Pahissa A. Epidemiology, risk factors and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, from 2002 to 2003. J Clin Microbiol 2006; 44: 1681-1685.
2. Girmenia CP, Martino F, De Bernardis F et al. Rising incidence of Candida parapsilosis fungemia in patients with hematologic malignancies: clinical aspects, predisposing factors and differential pathogenicity of the causative strains. Clin Infect Dis 1996; 23: 506-514.
3. Pfaller MA, Diekema DJ. Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J Clin Microbiol 2002; 40: 3551-3557.
4. Roy B, Meyer SA. Confirmation of the distinct genotype groups within the form species Candida parapsilosis. J Clin Microbiol 1998; 36: 216-218.
5. Tavanti A, Davison AD, Grow NAR, Maiden MCJ, Odds FC. Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III. J Clin Microbiol 2004; 43: 284-292.
6. Tavanti A, Hensgens LAM, Ghelardi E, Campa M, Senesi S. Genotyping of Candida orthopsilosis clinical isolates by amplification fragment length polymorphism reveals genetic diversity among independent isolates and strain maintenance within patients. J Clin Microbiol 2007; 45: 1455-1462.
7. Trofa D, Gácser A, Nosanchuk JD. Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev 2008; 21: 606-625.
8. Gómez-López A, Alastruey-Izquierdo A, Rodríguez D et al. Prevalence and susceptibility of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain. Antimicrob Agents Chemother 2008; 52: 1506-1509.
9. Kuhn DM, Mukherjee PK, Clark TA et al. Candida parapsilosis characterization in an outbreak setting. Emerg Infect Dis 2004; 10: 1074-1081.
10. Lockhart SR, Messer SA, Pfaller MA, Diekema DJ. Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis, in comparison to the closely-related species Candida parapsilosis. J Clin Microbiol 2008; 46: 2659-2664.
11. McGinley KJ, Larson EL, Leyden JJ. Composition and density of microflora in the subungual space of the hand. J Clin Microbiol 1988; 26: 950-953.
12. Pfaller MA, Barry AL. Evaluation of a novel colorimetric broth microdilution method for antifungal susceptibility testing of yeast isolates. J Clin Microbiol 1994; 32: 1992-1996.
13. Pfaller MA, Messer SA, Hollis RJ. Variation in DNA subtype, antifungal susceptibility, and slime production among clinical isolates of Candida parapsilosis. Diagn Microbiol Infect Dis 1995; 21: 9-14.
14. Asbeck E, Clemons KV, Martinez M, Tong A, Stevens DA. Significant differences in drug susceptibility among species in the Candida parapsilosis group. Diagn Microbiol Infect Dis 2008; 62: 106-109.
15. Pfaller MA, Diekema DJ, Gibbs DL et al. Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol 2005; 46: 842-849.
16. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 133-163.
17. Ramage G, Walle KV, Wikes BL, López-Ribot JL. Standarized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother 2001; 45: 2475-2479.
18. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeast, 3rd edn. Approved standard M27-A3. Wayne, PA: CLSI, 2008.
19. Enger L, Joly S, Pujol C, Simonson P, Pfaller M, Soll DR. Cloning and characterization of a complex DNA fingerprinting probe for Candida parapsilosis. J Clin Microbiol 2001; 39: 658-669.
20. Tumbarello M, Posteraro B, Trecarichi EM et al. Biofilm production by Candida species and inadequate antifungal therapy as predictor of mortality for patients with candidemia. J Clin Microbiol 2007; 45: 1843-1850.
21. Song J, Shin JH, Shint DH et al. Differences in biofilm production by three genotypes of Candida parapsilosis from clinical sources. Med Mycol 2005; 43: 657-661.
22. Branchini ML, Pfaller MA, Rhine-Chalberg J, Frempong T, Isenberg HD. Genotypic variation and slime production among blood and catheter isolates of Candida parapsilosis. J Clin Microbiol 1994; 32: 452-456.
23. Ruzicka F, Hola M, Votava M, Tejkalova R. Importance of biofilm in Candida parapsilosis and evaluation of its susceptibility to antifungal agents by colorimetric method. Folia Microbiology 2007; 52: 209-214.
24. Safdar A, Perling DS, Armstrong D. Hematogenous infections due to Candida parapsilosis: changing trends in fungemic patients at a comprehensive cancer center during the last four decades. Diagn Microbiol Infect Dis 2002; 44: 11-16.
25. Sarvikivi E, Lyytikainem O, Soll DR et al. Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal care unit. J Clin Microbiol 2005; 43: 2729-2735.
26. Shin JH, Kee SJ, Shin MG et al. Biofilm production by isolates of Candida species recovered from nonneutropenic patients: comparison of bloodstream isolates with isolates from other sources. J Clin Microbiol 2002; 40: 1244-1248.
27. Soll DR. The ins and outs of DNA fingerprinting the infectious fungi. Clin Microbiol Rev 2000; 13: 332-370.
28. Silva AP, Miranda IM, Lisboa C, Pina-Vaz C, Rodrigues AG. Prevalence, distribution and antifungal susceptibility profile of Candida parapsilosis, C. orthopsilosis and C. metapsilosis in a tertiary care hospital. J Clin Microbiol 2009; 47: 2392-2397.
29. Kuhn DM, Chandra J, Mukherjee PK, Ghannoum AM. Comparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces. Infect Immun 2002; 70: 878-888.
30. Katragkou A, Chatzimoscho A, Simitsopoulou M et al. Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms. Antimicrob Agents Chemother 2008; 52: 357-360.